Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="41570" type="General" weightage="100" keywordseo="zimbabwe" source="Orion">Zimbabwe</keyword> made it to the Super 12 stage of the T20 World Cup for the first time after an easy five-wicket win over <keyword id="44181" type="General" weightage="80" keywordseo="scotland" source="Orion">Scotland</keyword> in a Group B match here on Friday. The win ensured Group B the top spot for Zimbabwe as they joined India, Pakistan, South Africa, Bangladesh and Netherlands in the Group 2 of Super 12. For Scotland, it was the end of their campaign after the loss. Pacer Tendai Chatara led a spectacular bowling show with figures of 4-1-14-2 as Zimbabwe restricted Scotland to a below-par 132 for six. Chatara, who also became the first from Zimbabwe to take 50-plus wickets in T20 Internationals, checked the run flow with his accurate bowling. Left-arm pacer Richard <keyword id="14754768" type="General" weightage="80" keywordseo="ngarava" source="Orion">Ngarava</keyword> (2/28) was a tad expensive, but he also gave a twin blow to Scotland who never managed to get going after captain Richie Berrington opted to bat. In reply, Zimbabwe cantered home in 18.3 overs with their star all-rounder Sikandar <keyword id="169300" type="General" weightage="80" keywordseo="raza" source="Orion">Raza</keyword> slamming a 23-ball 40, studded with three fours and two sixes. Raza earlier chipped in with 1/20 with his off-spin to be adjudged man-of-the-match. "I don't think anyone could explain what it means. We've had the whole country behind us," Zimbabwe captain Craig Ervine said about making Super 12 for the first time. "The cricket we've played coming into the tournament has been special, so credit to the boys. We are looking forward to travelling around Australia now." Ervine top-scored for Zimbabwe with a 54-ball 58 as he anchored the chase after they were reduced to 7 for 2 inside two overs. First, he put together 35 from 39 balls with Sean Williams to repair the damage before Raza's impactful knock dashed Scotland's hopes of making the Super 12. The duo put together 64 from 43 balls in their fifth wicket stand. Earlier, Scotland opener George <keyword id="6351603" type="General" weightage="80" keywordseo="munsey" source="Orion">Munsey</keyword> (54 from 51b; 7x4) held the innings at one end and put together 40 runs with his skipper Berrington (13) but they never managed to step up their run rate. Berrington was dismissed by Raza, while Munsey became Ngarava's second victim. The Scots could not even manage to hit a six, which summed up the impressive Zimbabwean bowling effort. "I felt we were 25-30 runs short with the bat, a few more would have allowed us to create more pressure in the chase," Berrington said. "We've played some good cricket, so disappointing we didn't execute with the bat today. We can walk away proud with our performances, take a lot of positives from that moving forward," he added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/international/news/the-number-of-asylum-seekers-arriving-in-cyprus-has-doubled-so-far-this-year/articleshow/95002011.cms">The number of asylum seekers arriving in Cyprus has doubled so far this year</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/international/news/diwali-to-be-public-school-holiday-in-new-york-city-from-2023-mayor-says/articleshow/95002159.cms">Diwali to be public school holiday in New York City from 2023, Mayor says</a>

T20 World Cup: Zimbabwe makes it to Super 12 for the first time

<ul class="summary-list"><li>New York City's pace of housing construction has slowed to a trickle, despite a severe affordability crisis. </li><li>The governor's plan to boost housing failed in the legislature this year. </li></ul>New York's housing crisis isn't getting better any time soon.The borough of Manhattan, home to 1.7 million people, approved no new units of housing last month and just 10 buildings with 279 units in total were approved last month in the other four boroughs combined. City leaders are raising the alarm about the anemic pace of development."This should be considered a crisis. We have to fix this," Manhattan Borough President Mark Levine <a href="https://twitter.com/MarkLevineNYC/status/1688678516219351040" target="_blank" rel="noopener">said in a tweet.</a> Levine pointed to the steadily decreasing rate of construction in the city. The <a href="https://twitter.com/MarkLevineNYC/status/1688678517754490881" target="_blank" rel="noopener">city approved</a> 2,525 new units citywide and 1,208 in Manhattan in July 2013. In July 2022, it approved 527 citywide and 215 in Manhattan. This is part of a longer-term trend in the Big Apple, which has constructed far fewer units of new housing than it needs in recent years. Demand is far outstripping supply, driving rent and home prices through the roof. Over the last decade the city has gained <a href="https://gothamist.com/news/as-nyc-housing-crisis-worsens-mayor-adams-calls-for-500000-new-units-by-2032" target="_blank" rel="noopener">about four times as many new residents</a> as it has new homes. In 2019, the New York metro area needed more than <a href="https://www.nytimes.com/2022/08/01/nyregion/nyc-affordable-apartment-rent.html" target="_blank" rel="noopener">340,000 new homes</a>. At this point, half of all of New York City's working-age households can't afford housing and other essential goods, <a href="https://www.businessinsider.com/half-of-nyc-residents-cant-afford-housing-food-healthcare-report-2023-4">a recent report found</a>. Levine has <a href="https://www.manhattanbp.nyc.gov/initiatives/housing-manhattanites/" target="_blank" rel="noopener">a housing plan</a> for his borough that identifies about 200 sites in Manhattan where he wants to see more than 70,000 new homes constructed. These <a href="https://www.nytimes.com/2023/01/31/nyregion/manhattan-housing-vacant-buildings.html" target="_blank" rel="noopener">sites include</a> empty manufacturing space, an abandoned bus depot, and an unused Post Office building. Restrictive zoning and building code regulations,and the <a href="https://www.thecity.nyc/housing/2022/8/16/23309006/421a-affordable-housing-expired" target="_blank" rel="noopener">expiration of a key tax incentive</a> — known as 421-a — for developers are among the many reasons for New York City's slow rate of residential construction. Other city and state leaders have also been pushing for more housing as the affordability crisis worsens. New York City Mayor Eric Adams has a plan that aims to build 500,000 new homes by 2032, what he's called a "moonshot" goal. But the city <a href="https://www.thecity.nyc/2022/9/27/23373855/affordable-housing-crisis-city-council-eric-adams-throgs-neck" target="_blank" rel="noopener">needs 560,000 new homes by 2030</a> to meet current and future demand. New York Gov. Kathy Hochul attempted to pass a housing reform package this year that would have boosted the housing supply in New York City and its suburbs by 3% over the next decade. The <a href="https://www.governor.ny.gov/programs/new-york-housing-compact" target="_blank" rel="noopener">New York Housing Compact</a> aimed to build 800,000 new units, with new housing concentrated near transit stations — and it would have extended the 421-a tax break, which has encouraged significant housing development. But the effort failed after Republican and centrist Democratic lawmakers opposed it. A big portion of the opposition to the legislation came from <a href="https://www.businessinsider.com/rich-new-york-suburbs-losing-minds-hochul-plan-increase-housing-2023-4">suburban areas around New York City</a> that didn't want to see more density in their communities.Last month, the governor's office <a href="https://www.nytimes.com/2023/07/18/nyregion/housing-crisis-421a-hochul.html" target="_blank" rel="noopener">announced executive actions</a> aimed at boosting housing construction that include tax incentives for developers and an effort to allow new housing on state-owned land. It's not just Manhattan that's been building very little housing. The suburbs of New York City have also approved and constructed very few new units in recent years. The town of Munsey Park in Nassau County on Long Island permitted a total of four new single-family homes between between 2010 and 2021, Politico <a href="https://www.politico.com/newsletters/weekly-new-york-real-estate-infrastructure/2023/08/07/going-town-by-town-on-the-paltry-housing-growth-in-the-suburbs-00109939" target="_blank" rel="noopener">reported</a> based on Census data <a href="https://www.governor.ny.gov/new-york-state-housing-statistics" target="_blank" rel="noopener">collected by the governor's office</a>. Similarly, the city of Rye in Westchester County approved just 77 new housing permits, 65 of which were for single-family homes, during the same period of time. But not all of the Big Apple's suburbs are failing to take the housing shortage seriously. Over in New Jersey, Jersey City is building a significant amount of new housing — and even <a href="https://www.bloomberg.com/news/features/2023-04-03/jersey-city-is-reimagining-public-housing-redevelopment" target="_blank" rel="noopener">redeveloping aging affordable housing</a>. Hudson County, which is the city's home, <a href="https://cbcny.org/research/strategies-boost-housing-production-new-york-city-metropolitan-area#:~:text=New%20York%20City%20issued%20building,which%20final%20data%20is%20available." target="_blank" rel="noopener">built new housing at twice the rate</a> that New York City did between 2010 and 2018.

Manhattan real estate is in 'crisis' as new construction flatlines, borough president says

<ul class="summary-list"><li>Researchers are testing the drug rapamycin to see if it can help old dogs live longer.</li><li>If it works, the same treatment could be adapted for humans.</li></ul>Every Wednesday morning for a full calendar year, Jake the golden retriever received a tasty glob of peanut butter with five tiny pills hidden inside it: Two blue, two white, one orange.Dennis the greyhound currently has a different Wednesday morning routine. A tantalizing slice of string cheese with three tiny pills wedged inside: One blue, two white. Nobody knows for sure yet, but it's possible these irresistible snacks — laced with mysterious pills — might be helping the old dogs live longer, healthier lives. And eventually, they could help humans live for longer too.Dennis and Jake, both 10 years old, are participants in the <a href="https://affiliate.insider.com?h=720c5321ae25fe70538481388a0ea5ca024013b736d3ea004f9e3cad081ae0b7&amp;postID=642749d8dda1a508762c8736&amp;site=in&amp;u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41586-021-04282-9" target="_blank" rel="nofollow noopener sponsored">Dog Aging Project</a>, a multi-part, multi-year study of tens of thousands of dogs nationwide. Jake and Dennis are part of one tightly controlled study within the project testing whether the cancer and transplant drug rapamycin may help dogs live longer.During the study, <a href="https://hospital.vetmed.wsu.edu/2022/03/28/dog-aging-project-triad-study/" target="_blank" rel="noopener">researchers will also be on the lookout</a> for whether rapamycin can help dogs stay healthier and fitter as they age. If the research is successful, it could be a big deal for humans too. Researchers hope that rapamycin might be a kind of fountain of youth in pill form: an anti-aging drug that could help people — and their pets — live longer, healthier lives.<h2>Dogs with more energy and less gray hair, or "Wishful thinking?" </h2><div type="image" title="dog and owner at home" height="902" width="1200" msid="99239436" hostid="261"></div>So far, more than 85 dogs including Dennis and Jake are involved in the rapamycin study, formally called TRIAD (Test of Rapamycin in Aging Dogs.) The research includes teams of veterinarians working in at least 15 different trial sites nationwide, from New York to Texas, Colorado, and — soon — California. It's all being spearheaded by longevity researchers <a href="https://live-uwhalo.pantheonsite.io/people/daniel-promislow/" target="_blank" rel="noopener">Daniel Promislow</a> and <a href="https://live-uwhalo.pantheonsite.io/people/matt-kaeberlein/" target="_blank" rel="noopener">Matt Kaeberlein</a> at the University of Washington School of Medicine and veterinarian <a href="https://vscs.tamu.edu/person/6067/" target="_blank" rel="noopener">Kate Creevy</a> at Texas A&amp;M, who are hoping to enroll 580 dogs in the study by 2025, and finish the study by 2028."They take blood, urine, fecal samples, they do blood pressure," said Jake's owner, Timothy Cleary.Jake "is getting more comprehensive physicals than I do," Cleary said, referencing the checkups the dog gets at the University of Georgia every six months, which can last for up to four hours. The dogs, and their owners, as well as researchers conducting the study, have no way of knowing exactly what dose of medication the dogs are taking, or if they're even on any medication at all. The study is designed so that while some dogs get medicine, other dogs get placebo pills. That way, researchers hope to actually figure out the real effect of this drug on dog lifespan. Cleary says it might be "wishful thinking" but he's convinced that after a few months on the pills, he started to notice a difference in his dog. "We'd throw a little lacrosse ball in the backyard, I'd see him jumping off our rock wall," Cleary said, "He just seemed to have more energy."Dennis's owner Veronica Munsey also said,"This could be totally wishful thinking," but she's almost certain her dog's hair, which had been going gray for some time, started to darken again after he began taking the weekly pills. <h2>Man's best lab partner</h2><div type="image" title="dog owner with her two greyhounds outside in the snow" height="625" width="833" msid="99239440" hostid="261"></div><a href="https://www.insider.com/what-is-rapamycin-and-how-does-it-help-prevent-aging-2023-3">Rapamycin</a> has been used for decades in humans who've received a kidney transplant. More recently, drug developers have discovered it can also help with certain <a href="https://medlineplus.gov/druginfo/meds/a609032.html#:~:text=Everolimus%20treats%20cancer%20by%20stopping%20cancer%20cells%20from%20reproducing%20and%20by%20decreasing%20blood%20supply%20to%20the%20cancer%20cells." target="_blank" rel="noopener">treatment-resistant cancers, by stopping cancer cells from reproducing</a>. It helps suppress key parts of the <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/rapamycin#:~:text=Rapamycin%20(Rapamune%2C%20Sirolimus)%20is,treat%20certain%20types%20of%20cancer." target="_blank" rel="noopener">immune system</a>, slowing down things like <a href="https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-020-00396-1" target="_blank" rel="noopener">tumor growth</a>, and stimulating a <a href="https://affiliate.insider.com?h=7306c3b33b095b2a541a6a60a8f8d11b0e438c05e6dd017da4b6dde3a70bed02&amp;postID=642749d8dda1a508762c8736&amp;site=in&amp;u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fcdd2008110%23%3A~%3Atext%3Drapamycin%252C%2520a%2520lipophilic%2520macrolide%2520antibiotic%2520that%2520is%2520a%2520well%252Destablished%2520inducer%2520of%2520autophagy" target="_blank" rel="nofollow noopener sponsored">cellular cleanup process</a> in the body which is similar to fasting.All of this appears to be good for immunity to viruses including <a href="https://health.uconn.edu/aging/wp-content/uploads/sites/6/2016/04/mTOR-inhibition-improves-immune-function-in-the-elderly.pdf" target="_blank" rel="noopener">the flu</a>, and possibly <a href="https://www.insider.com/heres-why-a-longevity-researcher-takes-rapamycin-for-joint-pain-2023-3#:~:text=and%20could%20maybe%20have%20a%20similar%20effect%20on%20COVID">COVID.</a> Scientists have also shown that rapamycin works to increase the lifespan of <a href="https://pubmed.ncbi.nlm.nih.gov/20074526/" target="_blank" rel="noopener">fruit flies</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348514/#:~:text=increases%20worm%20lifespan" target="_blank" rel="noopener">worms</a>, <a href="https://www.science.org/doi/10.1126/sciadv.abo5482#:~:text=Rapamycin%20can%20extend%20life%20span,receptor%20knockout%20mice%20(20)." target="_blank" rel="noopener">mice, and water fleas</a>. But the effects of rapamycin on aging dogs — and on <a href="https://www.insider.com/heres-why-a-longevity-researcher-takes-rapamycin-for-joint-pain-2023-3">aging people</a> — is still being studied. And the drug is not without risk factors: Because rapamycin suppresses the immune system, <a href="https://medlineplus.gov/druginfo/meds/a609032.html#:~:text=you%20may%20develop%20sores,your%20treatment%20with%20everolimus." target="_blank" rel="noopener">patients on the drug sometimes develop mouth sores, and can have slower healing times</a> for wounds and cuts.That's why researchers are studying the drug on dogs first, before moving to more expansive human clinical trials. <a href="mailto:kaeber@uw.edu" target="_blank" rel="noopener">Matt Kaeberlein</a>, co-director of the Dog Aging Project, told Insider that dogs are a great animal to use for research because they share our environment.Unlike yeast and flies, dogs don't live in laboratories; they roll around in the grass, sniff pollen and pollutants, and accompany us through the drive-thru, sometimes snagging bites of our food. The fact that a dog's life "mirrors the human environment gives us some reason to be more confident that this will in fact work in people," Kaeberlein said.<h2>A biotech startup is also testing aging pills for dogs — with one specifically formulated for larger breeds </h2><div type="image" title="picture of celine" height="1220" width="1626" msid="99239442" hostid="261"></div>Kaeberlein and the University of Washington team aren't the only ones testing anti-aging treatments on dogs.Celine Halioua, founder and CEO of biotech startup Loyal, is similarly dedicated to helping dogs live longer and stay healthier, with an eventual eye towards helping humans do the same. Loyal recently received what Halioua believes is the very first <a href="https://blog.loyalfordogs.com/loyals-latest-milestone-the-first-longevity-clinical-study-design-supported-by-the-fda/" target="_blank" rel="noopener">Food and Drug Administration-supported longevity study design</a>, for upcoming trials of two different drugs for aging dogs. No drug has ever been FDA approved for <a href="https://www.insider.com/metformin-diabetes-weight-loss-anti-aging-drug-long-covid-prevention-2023-2">aging as a condition</a> — in animals or in people — so if her trial is successful, it could be a watershed moment for a whole new area of drug development, discovering what scientists call geroprotectors, drugs that could help combat death."It's a very, very important milestone for the aging field, because if we want to have more aging drugs, we need to have a defined clinical path for a drug going from zero to market for aging," she told Insider. Loyal is working on developing <a href="https://loyalfordogs.com/products" target="_blank" rel="noopener">two different pills.</a> The first, called LOY-001, is designed to help bigger dogs live longer, by minimizing factors that promote premature aging among bigger breeds. The second, LOY-002, is one that Halioua says works a lot like rapamycin but is a different compound. It also mimics fasting and improves a dog's metabolism, and it could be used in dogs of all sizes, if trials show it works.<h2>Anti-aging drugs that don't break the bank</h2><div type="image" title="matt k with his dog" height="1199" width="1599" msid="99239444" hostid="261"></div>Halioua says that the anti-aging field often gets a bad reputation for being "associated with billionaires who wanna live forever," but what's great about developing drugs for dogs is it's exactly the opposite of that. Treatments need to be cheap, accessible, and super safe if dog owners are going to be willing to use them. "Our drugs are gonna be cash pay," she said. "We're not betting on insurance for marketing our drugs. And so by definition, anything we're developing would have to be accessible if we want it to be marketable at all." Eventually, the same model could be used for people, she suspects. "My vision of what an aging drug should be is just a daily, cheap pill that the vast majority of the older US population is on to reduce the risk and severity of future age-related diseases," she said. "It's kind of the ultimate preventative medicine."Kaeberlein, who isn't shy about admitting <a href="https://www.insider.com/heres-why-a-longevity-researcher-takes-rapamycin-for-joint-pain-2023-3">he's already tried rapamycin out on his own aging joints</a>, agrees with Halioua that yes, it would be fantastic to have a cheap salve for age-related decline in people some day, especially one that costs just a few bucks per pill. But, even if that's not possible, he'd still be satisfied with research that enables his own dog, and other pooches, to stick around just a little while longer. "If we can increase the healthy longevity of pet dogs, that would be fantastic," he said. "I'm a dog person and I can say I've achieved something important in my career if we have that impact."

Dogs owners are feeding their dogs cheap pills to help them live longer &mdash; if it works, it could be an anti-aging fix for people too

You Searched For "munsey" and got 4 results

T20 World Cup: Zimbabwe makes it to Super 12 for the first time

PTI

Manhattan real estate is in 'crisis' as new construction flatlines, borough president says

Eliza Relman

Dogs owners are feeding their dogs cheap pills to help them live longer if it works, it could be an anti-aging fix for people too

Hilary Brueck

2020 IPL auction will see these 332 players trying their luck under the hammer

BI India Bureau

Popular Keywords

Buying Guides